- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00410774
Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine and bevacizumab after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase I/II trial is studying the side effects of gemcitabine and bevacizumab and to see how well they work in treating patients with pancreatic cancer that has been completely removed by surgery.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the safety of adjuvant, fixed-dose rate gemcitabine hydrochloride and bevacizumab in patients with completely resected pancreatic cancer.
- Determine the 1-year disease-free survival rate in patients treated with this regimen.
Secondary
- Determine the 1- and 2-year overall survival rates in these patients.
- Determine the median disease-free survival rate in these patients.
- Determine the median overall survival rate in these patients.
OUTLINE: This is an open-label, non-randomized study.
Patients receive gemcitabine hydrochloride IV over 100 minutes followed by bevacizumab* IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
NOTE: *The first dose of bevacizumab is not administered until after 6 weeks have passed since surgery.
After completion of study therapy, patients are followed periodically for 18 months.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
San Francisco, California, Forente stater, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Completely resected disease
Underwent 1 of the following procedures 3-8 weeks ago:
- Standard pancreaticoduodenectomy (for tumors of the pancreatic head)
- Distal pancreatectomy (for tumors of the pancreatic tail)
No grossly positive surgical margins
- Positive microscopic margins allowed
- Nonmeasurable disease
- No known CNS disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after completion of study therapy
- CA 19-9 ≤ 2.5 times upper limit of normal (ULN)
- Absolute neutrophil count ≥ 1,500/mm³
- Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)
- Platelet count ≥ 100,000/mm³
- INR ≤ 1.5 (except in patients receiving full-dose warfarin)
- Bilirubin ≤ 2.0 mg/dL
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 2.0 mg/dL
- No clinically significant impairment of renal function
No postoperative complications, including any of the following:
- Wound dehiscence or infection
- Intra-abdominal abscess
- Pancreatic or biliary leak or fistula
- Grade 3 or 4 delayed hemorrhage (occurring > 5 days postoperatively)
- Bowel perforation
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess within the past 6 months
- No history of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates use of the study drugs or renders the patient at high risk of treatment-related complications
- No other cancer within the past 5 years except basal cell or squamous cell skin cancer
No history of serious systemic disease, including any of the following:
- Myocardial infarction or unstable angina within the past 12 months
- New York Heart Association class II-IV congestive heart failure
Unstable symptomatic arrhythmia requiring medication
- Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
- No history of stroke or transient ischemic attack
- No symptomatic peripheral vascular disease
- No significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- No inadequately controlled hypertension (i.e., blood pressure > 150/100 mm Hg on antihypertensive medication)
- No prior hypertensive crisis or hypertensive encephalopathy
- No proteinuria (defined as urine protein:creatinine ratio ≥ 1.0 OR proteinuria ≥ 2+ by dipstick urinalysis OR protein > 1 g by 24-hour urine collection)
- No serious, nonhealing wound or ulcer
- No evidence of bleeding diathesis or coagulopathy
- No significant traumatic injury within the past 28 days
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy or radiotherapy for pancreatic cancer
- No prior systemic or investigational therapy for pancreatic cancer
- No major surgical procedure (except for resection of pancreatic cancer) or open biopsy within the past 28 days
- No fine-needle aspiration or core biopsy within the past 7 days
- No anticipated need for a major surgical procedure during study treatment
No concurrent newly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs)
- Concurrent chronic-dose NSAIDs for analgesia are allowed
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Safety of gemcitabine when administered with bevacizumab as assessed by NCI CTCAE v3.0
|
Disease-free survival rate at 1 year
|
Sekundære resultatmål
Resultatmål |
---|
Overall survival rate at 1 and 2 years
|
Median disease-free survival rate at 1 and 2 years
|
Median overall survival rate at 1 and 2 years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Andrew Ko, MD, University of California, San Francisco
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Sykdommer i det endokrine systemet
- Neoplasmer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer i bukspyttkjertelen
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Gemcitabin
- Bevacizumab
Andre studie-ID-numre
- CDR0000517330
- UCSF-06451
- UCSF-H12191-28980-01
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bukspyttkjertelkreft
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaNederland
-
Thomas Jefferson UniversityUkjentBukspyttkjertelfistel | Distal pankreatektomikomplikasjoner | Falciform Patch Pancreatic Closure | Fibrinlim bukspyttkjertellukkingForente stater
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbeidspartnereRekrutteringBukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannia
-
Chinese PLA General HospitalRekrutteringNeoplasmer i bukspyttkjertelen | Bukspyttkjertelkreft | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruIkke lenger tilgjengeligKarsinoide svulster | Islet Cell (Pancreatic NET) | Andre nevroendokrine svulsterForente stater
Kliniske studier på adjuvant terapi
-
Arizona State UniversityRekrutteringEffekten av START (Startle Rehabilitation Therapy) i behandlingen Slagindusert afasi/apraksi (START)Slag | Afasi | Apraxia av taleForente stater
-
Arizona State UniversityRekruttering
-
Arizona State UniversityRekruttering
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RekrutteringPerifer nevropatiForente stater
-
VA Pacific Islands Health Care SystemUnited States Department of Defense; Charles River AnalyticsFullførtSinne | Stresslidelser, posttraumatiskForente stater
-
Douglas MenninWeill Medical College of Cornell University; Kent State UniversityFullførtGeneralisert angstlidelse | Depresjon, angst | Angstlidelser og symptomer | Emosjonell dysfunksjonForente stater
-
The Central and Eastern European Gynecologic Oncology...RekrutteringLivmorhalskreftTsjekkia
-
Shanghai Zhongshan HospitalRekrutteringKirurgi | Resektabel kreft i bukspyttkjertelen | Adjuvant kjemoradioterapiKina
-
Kessler FoundationUkjentBrystkreftForente stater
-
Tao OUYANGAktiv, ikke rekrutterende